The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Accelerated Titration Designs for Phase I Clinical Trials in Oncology
Abstract
BACKGROUND: Many cancer patients in phase I clinical trials are treated at doses of chemotherapeutic agents that are below the biologically active level, thus reducing their chances for therapeutic benefit. Current phase I trials often take a long time to complete and provide little information about interpatient variability or cumulative toxicity. PURPOSE: Our objective was to develop alternative designs for phase I trials so that fewer patients are treated at subtherapeutic dose levels, trials are of reduced duration, and important information (i.e., cumulative toxicity and maximum tolerated dose) needed to plan phase II trials is obtained. METHODS: We fit a stochastic model to data from 20 phase I trials involving the study of nine different drugs. We then simulated new data from the model with the parameters estimated from the actual trials and evaluated the performance of alternative phase I designs on this simulated data. Four designs were evaluated. Design 1 was a conventional design (similar to the commonly used modified Fibonacci method) using cohorts of three to six patients, with 40% dose-step increments and no intrapatient dose escalation. Designs 2 through 4 included only one patient per cohort until one patient experienced dose-limiting toxic effects or two patients experienced grade 2 toxic effects (during their first course of treatment for designs 2 and 3 or during any course of treatment for design 4). Designs 3 and 4 used 100% dose steps during this initial accelerated phase. After the initial accelerated phase, designs 2 through 4 resorted to standard cohorts of three to six patients, with 40% dose-step increments. Designs 2 through 4 used intrapatient dose escalation if the worst toxicity is grade 0-1 in the previous course for that patient. RESULTS: Only three of the actual trials demonstrated cumulative toxic effects of the chemotherapeutic agents in patients. The average number of patients required for a phase I trial was reduced from 39.9 for design 1 to 24.4, 20.7, and 21.2 for designs 2, 3, and 4, respectively. The average number of patients who would be expected to have grade 0-1 toxicity as their worst toxicity over three cycles of treatment is 23.3 for design 1, but only 7.9, 3.9, and 4.8 for designs 2, 3, and 4, respectively. The average number of patients with grade 3 toxicity as their worst toxicity increases from 5.5 for design 1 to 6.2, 6.8, and 6.2 for designs 2, 3, and 4, respectively. The average number of patients with grade 4 toxicity as their worst toxicity increases from 1.9 for design 1 to 3.0, 4.3, and 3.2 for designs 2, 3, and 4, respectively. CONCLUSION: Accelerated titration (i.e., rapid intrapatient drug dose escalation) designs appear to effectively reduce the number of patients who are under-treated, speed the completion of phase I trials, and provide a substantial increase in the information obtained.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pharmacological Basis of Therapeutics
(1976) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/33.4.373a · Cited by 8,209
Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
O'Quigley, J., Pepe, M., & Fisher, L. (1990) · Biometrics · doi:10.2307/2531628 · Cited by 1,577
Design and Analysis of Phase I Clinical Trials
Storer, B. E. (1989) · Biometrics · doi:10.2307/2531693 · Cited by 930
Some practical improvements in the continual reassessment method for phase I studies
Goodman, S. N., Zahurak, M. L., & Piantadosi, S. (1995) · Statistics in Medicine · doi:10.1002/sim.4780141102 · Cited by 472
CHOU, T.-C., & TALALAY, P. (2005) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1981.tb06218.x · Cited by 419
Potential roles for preclinical pharmacology in phase I clinical trials.
Collins, J. M., Zaharko, D. S., Dedrick, R. L., et al. (1986) · PubMed · Cited by 213
Self-citationRatain, M. J., Mick, R., Schilsky, R. L., & Siegler, M. (1993) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/85.20.1637 · Cited by 190
Möller, S. (1995) · Statistics in Medicine · doi:10.1002/sim.4780140909 · Cited by 156
Therapeutic response in phase I trials of antineoplastic agents.
Estey, E., Hoth, D. F., Simon, R., Marsoni, S., Leyland-Jones, B., & Wittes, R. E. (1986) · PubMed · Cited by 139
Self-citationStudy designs for dose-ranging
Sheiner, L. B., Beal, S. L., & Sambol, N. C. (1989) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1989.108 · Cited by 109
Research works printed but not linked: 7
- Estey, 1986, Cancer treatment reports, 70, 1105
- Collins, 1986, Cancer treatment reports, 70, 73
- 1973, 68, 594, 10.1080/01621459.1973.10481389 · doi:10.1080/01621459.1973.10481389
- Piantadosi, 1996, Statistics in medicine, 15, 1605, 10.1002/(SICI)1097-0258(19960815)15:15<1605::AID-SIM325>3.0.CO;2-2 · doi:10.1002/(sici)1097-0258(19960815)15:15<1605::aid-sim325>3.0.co;2-2
- Mick, 1993, JNCI Journal of the National Cancer Institute, 85, 217, 10.1093/jnci/85.3.217 · doi:10.1093/jnci/85.3.217
- Shih, 1989, Statistics in medicine, 8, 583, 10.1002/sim.4780080507 · doi:10.1002/sim.4780080507
- Mick, 1994, JNCI Journal of the National Cancer Institute, 86, 1685, 10.1093/jnci/86.22.1685 · doi:10.1093/jnci/86.22.1685
Cited by
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Brunstein, C. G., Miller, J. S., Cao, Q., McKenna, D. H., Hippen, K. L., Curtsinger, J., DeFor, T., Levine, B. L., June, C. H., Rubinstein, P., et al. (2011) · Blood · doi:10.1182/blood-2010-07-293795 · Cited by 1,045
Dose Escalation Methods in Phase I Cancer Clinical Trials
Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp079 · Cited by 867
Clinical trial of blood-brain barrier disruption by pulsed ultrasound
Carpentier, A., Canney, M., Vignot, A., Reina, V., Beccaria, K., Horodyckid, C., Karachi, C., Leclercq, D., Lafon, C., Chapelon, J.-Y., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6086 · Cited by 757
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623
Metadata
- Authors
- Simon, R., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-08-06
- Volume
- 89
- Issue
- 15
- Pages
- 1138-1147
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2141086589
- Cited by
- 639
- References
- 12
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Accelerated Titration Designs for Phase I Clinical Trials in Oncology. https://app.cochat.ai/papers/10.1093/jnci/89.15.1138
- The paper
- Simon, R., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. (1997). Accelerated Titration Designs for Phase I Clinical Trials in Oncology. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/89.15.1138
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.